Journal of Antimicrobial Chemotherapy
-
Publication Venue For
-
Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone..
74:228-233.
2019
-
Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants..
73:3482-3487.
2018
-
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate..
73:2112-2119.
2018
-
Metrics for quantifying antibiotic use in the hospital setting: Results from a systematic review and international multidisciplinary consensus procedure.
73:vi50-vi58.
2018
-
Metrics to assess the quantity of antibiotic use in the outpatient setting: A systematic review followed by an international multidisciplinary consensus procedure.
73:vi59-vi66.
2018
-
Quality indicators assessing antibiotic use in the outpatient setting: A systematic review followed by an international multidisciplinary consensus procedure.
73:vi40-vi49.
2018
-
Quality indicators for responsible antibiotic use in the inpatient setting: A systematic review followed by an international multidisciplinary consensus procedure.
73:vi30-vi39.
2018
-
Tolerability profile of the current antifungal armoury..
73:i26-i32.
2018
-
The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis)..
71:ii31-ii36.
2016
-
High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors..
71:2874-2882.
2016
-
Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study..
71:2938-2944.
2016
-
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial..
71:2234-2240.
2016
-
Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial..
71:2022-2030.
2016
-
High prevalence of PI resistance in patients failing second-line ART in Vietnam..
71:762-774.
2016
-
Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients..
71:727-730.
2016
-
Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species..
70:1408-1411.
2015
-
Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae..
70:1203-1211.
2015
-
Treatment outcomes of surgery, antifungal therapy and immunotherapy in ocular and vascular human pythiosis: a retrospective study of 18 patients..
70:1885-1892.
2015
-
Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure..
69:1119-1126.
2014
-
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections..
67:1496-1502.
2012
-
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial..
67:715-722.
2012
-
Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors..
65:2063-2069.
2010
-
CANVAS 2: The second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
65:iv53-iv65.
2010
-
Antifungal serum concentration monitoring: an update..
61:17-25.
2008
-
Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-beta-lactamase VIM-1 in Greece..
59:578-579.
2007
-
Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA..
57:1240-1243.
2006
-
Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia..
55:721-726.
2005
-
Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials..
54:701-703.
2004
-
Emergence of fluoroquinolone resistance among Bacteroides species..
52:208-213.
2003
-
Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus..
51:1099-1102.
2003
-
siRNAs: a new wave of RNA-based therapeutics..
51:753-756.
2003
-
A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution..
51:453-457.
2003
-
Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis..
50:811-817.
2002
-
Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis..
48:479-485.
2001
-
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group..
46:775-784.
2000
-
In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp..
44:223-228.
1999
-
In-vitro modelling of the bactericidal activity of teicoplanin versus flucloxacillin as used in surgical prophylaxis, against Staphylococcus aureus.
39:477-481.
1997
-
The effect of burn wound surgery and teicoplanin on the bactericidal activity of polymorphonuclear leucocytes against Staphylococcus aureus..
36:851-855.
1995
-
Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis..
33:73-81.
1994
-
Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and beta-lactamase inhibitor combinations..
28:855-867.
1991
-
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis..
26:387-397.
1990
-
Differential inhibition of HIV-1 cell binding and HIV-1-induced syncytium formation by low molecular weight sulphated polysaccharides..
25:313-318.
1990
-
Enhancement of the activity of cefotaxime by iron-binding proteins..
25:479-481.
1990
-
In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approach..
23:353-361.
1989
-
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits..
16:81-86.
1985
-
Pharmacokinetics of N-formimidoyl thienamycin and influence of a renal dipeptidase inhibitor in experimental meningitis..
12:39-45.
1983
-
Lack of disulfiram--like reactions with ceftizoxime..
10 Suppl C:129-133.
1982
-
Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates..
9:183-194.
1982
-
Cephradine concentrations in serum, pleural fluid, pleura, and lung of normal rabbits..
8:345-346.
1981
-
Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulphamethoxazole in experimental meningitis..
8:49-58.
1981
-
Antibiotic concentrations in human parapneumonic effusions..
7:171-177.
1981
-
Penetration of cephradine into normal, inflammatory, and infected pleural fluids in rabbits..
6:143-149.
1980
-
Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination..
4:375-380.
1978
-
Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy.
46:775-784.